NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Trial Profile

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs Tazemetostat (Primary)
  • Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Histiocytosis; Langerhans cell histiocytosis; Lymphoma; Medulloblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Pediatric MATCH
  • Most Recent Events

    • 12 Apr 2018 Planned End Date changed from 30 Apr 2022 to 30 Sep 2024.
    • 12 Apr 2018 Planned primary completion date changed from 30 Apr 2022 to 30 Sep 2024.
    • 24 Jul 2017 Status changed from not yet recruiting to recruiting according to an Epizyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top